Authored by Manni Mohyuddin, published on 2026-05-28 01:04:35.0
Treatment algorithm for transplant ineligible multiple myeloma. For frail patients, anti-CD38 best tolerated drug, other agents can be added as tolerable.
Backbone regimen: CD38 mAb + Len/dex
Dexamethasone should be discontinued by month 6, and taper started Cycle 3 onwards
Discuss the addition of once a week bortezomib*
* If willing to accept increased risk of neuropathy for better PFS/MRD (we do not know if OS better). What bortezomib adds trade off image